Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Natura:	Articolo
Lingua:	English
Pubblicazione:	Wiley 2023-08-01
Serie:	ESC Heart Failure
Soggetti:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Accesso online:	https://doi.org/10.1002/ehf2.14304

Documenti analoghi

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
di: Douglas B. Johnson, et al.
Pubblicazione: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
di: Federica Costa, et al.
Pubblicazione: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
di: Laura I. Yousif, et al.
Pubblicazione: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
di: Vickram A S, et al.
Pubblicazione: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
di: Ruby Dhar, et al.
Pubblicazione: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
di: Kazuhiko Hashimoto, et al.
Pubblicazione: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
di: Jing Huang, et al.
Pubblicazione: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
di: Juwon Lee, et al.
Pubblicazione: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
di: Ruiting Li, et al.
Pubblicazione: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
di: Sai Mummareddy, et al.
Pubblicazione: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
di: Tianrui Yang, et al.
Pubblicazione: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
di: Jan Willem Kleinovink, et al.
Pubblicazione: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
di: Sebastian Marwitz, et al.
Pubblicazione: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
di: Yavar Shiravand, et al.
Pubblicazione: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
di: YU Lin, et al.
Pubblicazione: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
di: Ahmed M. Basudan
Pubblicazione: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
di: Gabriel Surdacki, et al.
Pubblicazione: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
di: Andreas von Knethen, et al.
Pubblicazione: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
di: Alberto Bongiovanni, et al.
Pubblicazione: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
di: Ya Xu, et al.
Pubblicazione: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
di: Edyta Zyla, et al.
Pubblicazione: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
di: Emily Hensler, et al.
Pubblicazione: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
di: Mihnea Dragomir, et al.
Pubblicazione: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
di: Maria Georganaki, et al.
Pubblicazione: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
di: William L. Redmond, et al.
Pubblicazione: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
di: Reid P. Bissonnette, et al.
Pubblicazione: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
di: Ji Won Han, et al.
Pubblicazione: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
di: Kübra KAHVECİ, et al.
Pubblicazione: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
di: Zachary S. Buchwald, et al.
Pubblicazione: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
di: Amjad Zafar, et al.
Pubblicazione: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
di: Jiaxin Zhou, et al.
Pubblicazione: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
di: Adel Naimi, et al.
Pubblicazione: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
di: Zhanjun Guo, et al.
Pubblicazione: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
di: Troy A McEachron, et al.
Pubblicazione: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
di: Deniz Can Guven, et al.
Pubblicazione: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
di: Kuti Baruch, et al.
Pubblicazione: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
di: Leona Raskova Kafkova, et al.
Pubblicazione: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
di: Shuai Wang, et al.
Pubblicazione: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
di: Silvia Pesce, et al.
Pubblicazione: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
di: Boris Klebansky, et al.
Pubblicazione: (2024-05-01)